Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boman, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boman, G.
(Chest. 1972;61:533-538.)
© 1972 American College of Chest Physicians

Rifampin-Isoniazid Compared with PAS-Isoniazid-Streptomycin in Initial Treatment of Pulmonary Tuberculosis

A Controlled Cooperative Trial

Gunnar Boman M.D.1

1 Dept. of Thoracic Medicine, Karolinska Sjukhuset, Stockholm, Sweden

In view of our results we consider refampin plus isoniazid a highly effective combination in the treatment of newly detected advanced pulmonary tuberculosis, both in terms of speed of elimination of bacilli and roentgenologic improvement. The frequency of side effects is lower and patient acceptance is better than with PAS plus isoniazid plus streptomycin. Considering the risk of primary resistance to isoniazid, we suggest giving a third drug, streptomycin or ethambutol, until the initial susceptibility test is available, at least in highly infectious and far advanced cases.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the American College of Chest Physicians.